Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells for Drug Discovery & Toxicity Screening 2017

Tommy Andersson's Biography



Tommy Andersson, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca R&D Mölndal

Tommy B. Andersson is a Senior Principal Scientist at Cardiovascular and Metabolic Disease, DMPK, AstraZeneca R&D Gothenburg. He is also a visiting professor at the Karolinska institute, department of Physiology and Pharmacology, section of pharmacogenetics. He has over 20 years scientific, management and project experience within the pharmaceutical industry and academia covering drug metabolism, dispositon and pharmacokinetics in projects from early drug discovery to life cycle management. Recently attanetion has been paid to stem cell technology and organotypic microphysiological systems and its applications in drug discovery. He is the author of 158 peer reviewed scientific publications.

Tommy Andersson Image

Novel Microphysiological Multi-Organ Systems for Studies of Human Metabolic Diseases in Drug Discovery

Monday, 10 July 2017 at 12:00

Add to Calendar ▼2017-07-10 12:00:002017-07-10 13:00:00Europe/LondonNovel Microphysiological Multi-Organ Systems for Studies of Human Metabolic Diseases in Drug DiscoveryStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Currently used pre-clinical models often suffer from poor translation of drug responses to the patient due to the limited knowledge gained in the efficiency and mode of action of the drug candidate. This contributes to high attrition rates in early clinical programs. Multi organ-on-a-chip emulating human physiology have the possibility to improve success rate by mimicking the human disease state and improve selection of the right targets and compounds early in drug discovery. Such models will not only improve translation to patients but also reduce time spent in early clinical programs as well as reducing the needs for animal models.  We developed a human liver - pancreatic islets chip model. The model allows cross talk between cells from both organs in a fluidic system and responds in a physiological way to glucose load by increased insulin secretion leading to increased glucose consumption (figure). Initial studies indicate that the model can become insulin resistant and thus can be used as a metabolic disease model.  Ongoing studies are investigating how insulin resistance in liver cells effects islet function by using the insulin receptor antagonists.


Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com